Literature DB >> 15642916

Abeta vaccination effects on plaque pathology in the absence of encephalitis in Alzheimer disease.

E Masliah1, L Hansen, A Adame, L Crews, F Bard, C Lee, P Seubert, D Games, L Kirby, D Schenk.   

Abstract

The authors report a patient with Alzheimer disease (AD) without encephalitis who was immunized with AN-1792 (an adjuvanted formulation of Abeta-42). There were no amyloid plaques in the frontal cortex and abundant Abeta-immunoreactive macrophages, but tangles and amyloid angiopathy were present. The white matter appeared normal and minimal lymphocytic infiltration in the leptomeninges was observed. This case illustrates the effects of an Abeta-based immunization on AD pathogenesis in the absence of overt meningoencephalitis and leukoencephalopathy.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15642916     DOI: 10.1212/01.WNL.0000148590.39911.DF

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  153 in total

Review 1.  Some evolutionary perspectives on Alzheimer's disease pathogenesis and pathology.

Authors:  Daniel J Glass; Steven E Arnold
Journal:  Alzheimers Dement       Date:  2011-12-03       Impact factor: 21.566

Review 2.  Current therapeutic targets for the treatment of Alzheimer's disease.

Authors:  Joshua D Grill; Jeffrey L Cummings
Journal:  Expert Rev Neurother       Date:  2010-05       Impact factor: 4.618

3.  Low concentrations of anti-Aβ antibodies generated in Tg2576 mice by DNA epitope vaccine fused with 3C3d molecular adjuvant do not affect AD pathology.

Authors:  Nina Movsesyan; Hayk Davtyan; Mikayel Mkrtichyan; Irina Petrushina; Tigran Tiraturyan; Ted Ross; Michael G Agadjanyan; Anahit Ghochikyan; David H Cribbs
Journal:  Hum Gene Ther       Date:  2010-11       Impact factor: 5.695

4.  A single ascending dose study of bapineuzumab in patients with Alzheimer disease.

Authors:  Ronald S Black; Reisa A Sperling; Beth Safirstein; Ruth N Motter; Allan Pallay; Alice Nichols; Michael Grundman
Journal:  Alzheimer Dis Assoc Disord       Date:  2010 Apr-Jun       Impact factor: 2.703

Review 5.  Amyloid-modifying therapies for Alzheimer's disease: therapeutic progress and its implications.

Authors:  Meaghan C Creed; Norton W Milgram
Journal:  Age (Dordr)       Date:  2010-04-20

Review 6.  Drug targets from genetics: α-synuclein.

Authors:  Karin M Danzer; Pamela J McLean
Journal:  CNS Neurol Disord Drug Targets       Date:  2011-09-01       Impact factor: 4.388

Review 7.  Transgenic mouse models of Alzheimer disease: developing a better model as a tool for therapeutic interventions.

Authors:  Masashi Kitazawa; Rodrigo Medeiros; Frank M Laferla
Journal:  Curr Pharm Des       Date:  2012       Impact factor: 3.116

8.  Increased T cell recruitment to the CNS after amyloid beta 1-42 immunization in Alzheimer's mice overproducing transforming growth factor-beta 1.

Authors:  Marion S Buckwalter; Bronwen S Coleman; Manuel Buttini; Robin Barbour; Dale Schenk; Dora Games; Peter Seubert; Tony Wyss-Coray
Journal:  J Neurosci       Date:  2006-11-01       Impact factor: 6.167

Review 9.  Immunotherapy targeting pathological tau protein in Alzheimer's disease and related tauopathies.

Authors:  Einar M Sigurdsson
Journal:  J Alzheimers Dis       Date:  2008-10       Impact factor: 4.472

Review 10.  Immunotherapeutic approaches for Alzheimer's disease in transgenic mouse models.

Authors:  Thomas Wisniewski; Allal Boutajangout
Journal:  Brain Struct Funct       Date:  2009-12-10       Impact factor: 3.270

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.